RE SOURCES

2 0 1 5 A N N U A L R E P O R T

UNDERS TANDING p.11

EXPERTISE IN SKIN HEALTH

S O CIE T Y p.14
OSTEOARTHRITIS: A CHALLENGE FOR MOBILITY

REP ORT ING p.26

BEHIND THE SCENES
IN ÉPERNON

S A G A p.30
Corporate Social
Responsibility:
Expanscience
introduces its “Better
Living Program”
 PRESERVE
THE BEAUTY
OF YOUR SKIN
with complete safety
for your baby
100%
*

COMPAT I B LE
WITH BREASTFEEDING
SAFE FOR
M OT H E R A N D BA B Y

STRETCH MARKS
* All Mustela® Maternity formulas have been evaluated to be suitable for breastfeeding.

SKIN COMFORT
FIRMING

BREASTFEEDING

CLINICALLY-PROVEN EFFICACY

MUSTELA,
®
THE SKINCARE EXPERT FOR BABIES AND MOTHERS-TO-BE FOR OVER 60 YEARS.
DIRECTOR OF PUBLICATIONS
Jean-Paul Berthomé

EDITORIAL DIRECTOR
Sébastien Sillon

EDITOR-IN-CHIEF
Emmanuelle Dumas

EDITORIAL MANAGER
Nolwenn Sassier-Le Goff

DESIGN, CREATION,

EDITORIAL
PRODUCTION AND PRINTING
Aristophane

This annual report is published

by Laboratoires Expanscience.

PHOTO©
Getty Images
Fotolia
Expanscience photo library
2015:
A PIVOTAL
Thomas Deron

YEAR

By printing this annual report

on FSC and European
Ecolabel approved offset
paper, Expanscience Cover Over the life of a company, some years have
is helping to protect © Getty Images
an especially decisive impact. At Laboratoires
the environment.
This document has been printed Expanscience, 2015 was undoubtedly one
by Ateliers Réunis, an of those years. It’s been decisive for the success
Imprimvert-certified printer.
of our products worldwide, for the production
Laboratoires Expanscience’s records set by our manufacturing site, and above
contribution to sustainable all for the milestones we have reached,
development has been
the transformations we have successfully navigated
recognized as exemplary by
the AFAQ 26000 assessment. and the ambitions we have set for ourselves.
In 2015, for the first time, our international sales
Laboratoires Expanscience
exceeded our sales in France. Moreover, in 2015
has been a signatory
of the United Nations Global we adopted a new business model in France
Compact since 2004. for Piasclédine 300, our drug for the treatment
of osteoarthritis. And in 2015 we drafted a five-year
Laboratoires Expanscience
is a member of the UEBT plan of commitments with regard to Corporate
for protecting biodiversity Social Responsibility, with the aim of pledging
and complying with fair
trade regulations. new commitments between now and 2020.

The environmental All of these events are described in this fourth

management system that
Laboratoires Expanscience issue of Re Sources and make 2015 a pivotal year and
has developed for its R&D a collective human accomplishment.
and production activities
is ISO 14001-certified. These events are the result of strategic decisions
but also, first and foremost, the outgrowth of our
Since 2009, Laboratoires employees’ commitment to innovate in order
Expanscience has been
a signatory of the Charter to protect the health of our patients and consumers.
for Responsible Communications You can read what those employees have to say
from the French Advertisers
Association.
throughout this report, and you’ll quickly
understand why we have chosen to feature
their comments prominently!

Enjoy your reading!

The editorial team

 THE DAILY
DIAPER CARE
THAT CHANGES
EVERYTHING

1 2 3
PREVENTS RELIEVES REPAIRS
IRRITATION AND REDNESS

HIGH TOLER ANCE

0 % FRPREAGRSERAVATI
NCE
VE

OUR COMMITMENTS

98 INGREDIENTS
OF NATURAL ORIGIN
PARABEN - PHTHALATE
PHENOXYETHANO L
DESIGNED TO MINIMIZE
ENVIRONMENTAL IMPACT

MUSTELA ® , IT ALL STARTS WITH SKIN

 2015 ANNUAL REPORT E X PA NS C I E N C E 03

06
BENCHMARKS

11
Key figures
for 2015

UNDERSTANDING
Expertise
in skin health
08
HIGHLIGHTS
One year,
10 new developments

14
SOCIETY
Osteoarthritis:
a challenge for mobility

21
FEATURE
At the heart
of Laboratoires
Expanscience

INTERVIEW
Jean-Paul Berthomé
CEO
30
SAGA
04 Corporate social
responsibility:
REPORTING Expanscience
IR&D and production: introduces its “Better
behind the scenes Living Program”
in Épernon

26 34
HERE & THERE
A stronger
presence on
5 continents

SELECTED
ITEMS
Focus on
Expanscience
39
products SPONSORSHIP
A commitment
17 without borders
INTERVIEW

JEAN-PAUL
BERTHOMÉ
/
Laboratoires
Expanscience
CEO
 2015 ANNUAL REPORT E X PA NS C I E N C E 05

HOW DO YOU REFLECT environmental and social concerns, WHAT ARE YOUR AMBITIONS
ON 2015? changing community attitudes toward FOR 2016?
businesses, etc.), we have defined a
— The past year has been one in new road map for the next five years. — We have objectives for advancing
which Expanscience demonstrated We’re calling this road map our “Better and capturing growth in each of our
its ability to adapt and pursue further Living Program,” and it contains our markets. First, we’re aiming for double-
international growth. In order to meet commitments for 2020, all aimed at taking digit growth for our Mustela brand in
the challenge of Piasclédine 300, our drug better care of each of our communities, the international market. This will be
for the treatment of osteoarthritis, being including patients, consumers and driven by expanded market share in Asia,
removed from the list of reimbursable employees. a launch in the South African market,
products in France, we adopted a new our continued positioning as a Premium
business model, called OTX*, and have brand in response to strong demand
succeeded in cementing our leadership worldwide, and our ongoing campaign
in pharmacies. Thanks to our energetic to roll out our new Mustela Maternity
distributors and the opening of new product line. In rheumatology, too, the
subsidiaries - five in three years, notably international market will be instrumental
in Canada and Russia in 2015 - we passed in driving growth, with the introduction of
a critical milestone: for the first time in “ THE EXPANSCIENCE Piasclédine 300 in Brazil. We also intend
our history, more than half of our turnover OF THE FUTURE IS to continue our progress in France in the
came from outside France. market for arthritis and osteoporosis by
A COMPANY WILLING strengthening our OTX model regarding
WHAT ASSESSMENT WOULD TO ADAPT, WITH Piasclédine 300 – which test laboratory
YOU GIVE FOR EACH BUSINESS? was successful - and by introducing a
ETHICS, RESPECT AND
first-line treatment for osteoporosis
— In a challenging environment, we A RESPONSIVE ATTITUDE. in menopausal women. Growth in our
have managed to expand our rheumatology cosmetic active ingredients business will
ALONG WITH ITS
business, thanks to our overall turnover be led by a portfolio enhanced with new,
from the portfolio and double-digit PRODUCTS, IT OFFERS natural-origin active ingredients that
growth abroad. With regard to our dermo- AN ARRAY OF SERVICES offer sensory appeal. Lastly, innovation
cosmetics business, the revitalization of remains our priority: we’ll be maintaining
our Mustela Bébé and Mustela Maternity TO PATIENTS AND our EV.E.I.L.S** research program in
product lines has borne fruit, and Mustela’s CUSTOMERS THROUGHOUT the fields of infant and pregnant women
market share has increased in every skin, which in 2016 will continue to power
country, with a strong contribution from THE WORLD. ” our expertise in skin health and our future
our subsidiaries in Turkey, Belgium, Brazil innovations.
and France. Cosmetic active ingredients
also posted solid growth, thanks to the WHAT DO YOU THINK EXPANSCIENCE
launch of two active ingredients and our WILL LOOK LIKE IN 2020?
efforts to capture new customers. Lastly,
the introduction of our Finhair Gé drug for — It will look like a company that
androgenic alopecia, and continued strong DURING THIS PAST YEAR YOU LED acquired the resources to change and
sales of Effizinc, used to treat mild acne, AN INITIATIVE REGARDING YOUR adapt, and that goes beyond its products
have boosted growth in dermatology. COMPANY’S IDENTITY AND CULTURE. to become something even more valuable
WHAT WAS YOUR OBJECTIVE? for patients and consumers. It will also
IN 2010 EXPANSCIENCE ADOPTED A be a more international company, with
NUMBER OF COMMITMENTS FOR 2015 —  During Expanscience’s current 75% of its turnover generated outside
WITH REGARD TO CORPORATE SOCIAL growth phase, we saw a need to look of France.
RESPONSIBILITY (CSR). WHAT HAVE once again at the powerful and unifying
* A model based on over-the-counter sales
BEEN THE RESULTS? characteristics that bind our workforce of Piasclédine 300 in connection with a medical
together, and the ways our employees prescription

— I’m proud of the path we have strive for innovation each day to preserve ** Evaluation of Early Infant Life: the Skin
taken. Thanks to the energetic efforts the health of our patients and consumers.  
of the entire workforce, we have fulfilled Our aim was not merely to promote
our commitments. Our CSR policy is an unity and a sense of belonging among
increasingly integral part of the company, our employees, but also to make us
and truly sets us apart in the eyes of more attractive to the candidates we
our target markets. It has won external hire in the future, notably overseas.
recognition in the form of 12 different Those considerations prompted us to
awards the company has received since adopt a campaign to voice our conviction
2012. Insofar as Expanscience and its that, as an employer: “Each one’s
ecosystem are confronted with new potential makes everyone’s success.”
challenges (international expansion,
 06 BENCHMARKS

BEN CH MAR KS

K EY FIGURES
FOR 2015

€272.3 M IN TURNOVER

TURNOVER BY ACTIVITY:

58.9%
DERMO-COSMETICS
36.5 %
RHEUMATOLOGY

3.1 %
0.1 % DERMATOLOGY
INDUSTRY

1.4 %
COSMETIC ACTIVE INGREDIENTS
 2015 ANNUAL REPORT E X PA NS C I E N C E 07

85
DISTRIBUTING COUNTRIES

977EMPLOYEES

14
SUBSIDIARIES: AUSTRALIA, BELGIUM, BRAZIL,
CANADA, FRANCE, ITALY, MEXICO, POLAND,
PORTUGAL, RUSSIA, SPAIN, SWITZERLAND,
TURKEY, UNITED STATES

66
MILLION PRODUCTS
MANUFACTURED

843
PATENTS REGISTERED
WORLDWIDE

TURNOVER
BY GEOGRAPHICAL AREA

INTERNATIONAL FRANCE

51.3 % 48.7 %
08 HIGHLIGHTS

HIGHLIGHTS

ONE YEAR,
10 NEW
DEVELOPMENTS

O3
OSTEOARTHRITIS:
STRONGER
MARKET
DOMINANCE
At a time when slow-acting anti-

O1 rheumatic drugs are no longer

reimbursable in France, Piasclédine 300
has managed to cement its leadership
FOR FEELING status in pharmacies and among

GOOD DURING O2
healthcare professionals through an
emphasis on medical prescriptions.

PREGNANCY Internationally, the drug has logged

The new Mustela Maternity

A NEW double-digit growth in turnover.

line is designed to preserve

the skin’s beauty while ensuring
DIGITAL
SHOWCASE
O4
the baby’s safety, with seven
expert treatments specially
formulated to address the various The expanscience.com website
ways skin can change during
pregnancy. Guaranteed safe
has been completely redesigned
to more closely reflect WORKING
for mother and child, clinically the company’s identity.
Contemporary, user-friendly
ALONGSIDE
proven to be effective, enjoyable
to use and made with ingredients and intuitive, the new site RESEARCHERS
of natural origin whenever immediately envelops visitors
in the world of Expanscience, As part of the Research on Osteo
possible, this new line of Mustela
from its know-how and services Arthritis Diseases (ROAD) project and in
products bears all the hallmarks
in the fields of osteoarthritis partnership with the Arthritis Foundation,
of the Mustela name.
and skin health to its expertise Laboratoires Expanscience are joining
in innovation, research and forces with seven basic research units at
development, along with an France’s Institute of Health and Medical
introduction to the company’s Research (INSERM) and National Center
products and its CSR policy. for Scientific Research (CNRS). The goal
As a true showcase for of the three-year program is to identify
Expanscience, it can be viewed new biomarkers for use in developing
on any medium (computer, innovative therapeutic strategies in the
tablet, smartphone). treatment of osteoarthritis.
 2015 ANNUAL REPORT E X PA NS C I E N C E 09

09
EXPANSCIENCE AT
THE VANCOUVER
O5 CONGRESS
CSR: At the 23rd World Congress of
Dermatology, held in Vancouver,
EXPANSCIENCE O7 Expanscience presented the
results of 10 years of research
HONORED into the skin of newborns and

ONCE AGAIN THE APP FOR children to more than 100

opinion-leaders in the field

Expanscience was awarded

NEW MOTHERS of dermatology from around

the top prize for its Corporate AND MOTHERS- the world. The WCD is a major
event on the calendar of the
Social Responsibility policy in
the “Governance, Ethics and TO-BE international dermatology
community.
Responsible Management” category
of the first-ever 2015 CSR Awards, Mustela has created “Mustela & me”
hosted by Les Entreprises du an innovative support program
Médicament (LEEM), a trade to ensure mothers have
organization for the French a fulfilling pregnancy. This free app,
pharmaceutical industry. available in five languages, offers
The independent jury specifically daily tips and advice before, during
praised the comprehensive nature and after pregnancy.
of the company’s policy, in which It was elected “Best Sport, Health
every employee has a role to play; and Wellness” app at France’s 2015
its deployment of an action plan
through a network of internal
App Awards six months after
its launch. 10
liaisons; and the way the policy was
developed in cooperation TWO NEW
with company stakeholders.
COSMETIC
O8 ACTIVE
INGREDIENTS
MUSTELA
O6 MOVES INTO
Capitalizing on its expertise
in plant extraction and the
INTERNATIONAL CANADA know-how of its research
teams, Expanscience expanded
SALES: A DECISIVE AND RUSSIA its offerings for the cosmetics
industry with two innovative and
MILESTONE To accelerate Mustela’s eco-designed active ingredients.
Pixalia, responsibly sourced
international growth,
For the first time in the history Expanscience opened two from Burkina Faso, acts on oily,
of Laboratoires Expanscience, new subsidiaries in Canada acne-prone skin in women
and thanks to the strong and Russia - high-potential and teenagers. Made from
performance of the Mustela markets where the dermo- maca, a plant cultivated in Peru,
brands and Piasclédine 300 on cosmetics brand was previously Macaline marks Expanscience’s
every continent, turnover from distributed by partners. Five new entry into the segment
international sales surpassed that subsidiaries have been created of active ingredients for the body,
of sales in France, which also in the span of three years. thanks to its threefold slimming,
rose. This brings the company one firming and draining action.
step closer to an objective that
Expanscience has set for 2020:
to obtain 75% of its turnover
from international markets.
 MUSTELA
CARE THAT IS NATURALLY SAFE AND
EFFECTIVE FOR YOUR SKIN

DID YOU KNOW...?

In light of the specific needs
of its target customers
and its strong commitment WE HAVE OPTED
to Corporate Social FOR “NATURALNESS” AS
Responsibility (CSR),
Expanscience has established A WAY TO PRESERVE DELICATE
its own natural products charter. SKIN MORE EFFECTIVELY.
Transparent and available to
the public at www.expanscience.com, WE SELECT THE BEST
the charter serves as a detailed INGREDIENTS OF NATURAL
specification for the Expanscience
personnel responsible ORIGIN IN ORDER TO PROVIDE
for formulations and procurement. SAFE, EFFECTIVE PRODUCTS
THAT ARE A PLEASURE
TO USE AND FRIENDLY
TO BOTH PEOPLE
AND THE ENVIRONMENT.

A NATURAL OIL
FOR PREVENTING
STRETCH MARKS QUANTIFIED NATURAL ORIGIN

Developed in collaboration with

healthcare professionals, including
Mustela has always looked pediatricians and dermatologists,
to the plant world to source the products in the Mustela Bébé
the main active ingredients and Mustela Maternity lines contain
that make up its products. an average of 92% and 86% ingredients
Made from 99% ingredients of natural origin respectively.
of natural origin*, Mustela
Maternity Stretch Marks
Prevention Oil is exemplary PRODUCTS THAT CONTAIN…
in its commitment to
naturalness. Its formula Mustela products have three types
combines five vegetable oils: of ingredients:
avocado, sunflower, baobab, — “natural” ingredients (water, oils,
pomegranate and musk rose. plant-based butters) that come
directly from nature;
Expanscience uses sustainable — ingredients of natural origin
sources of avocado (emulsifiers, gelling agents) that
and sunflower, with respect are obtained from nature but processed
for biodiversity as well as local using certain chemical procedures;
inhabitants. Its supply channels — selected synthetic ingredients
for plant-based raw materials (such as pH regulators), added solely
are subject to evaluation when no appropriate natural alternative
by the Union for Ethical is available.
BioTrade (UEBT) and include
precise traceability.
PRODUCTS THAT DO NOT CONTAIN...
In accordance with
To meet the needs of natural, sensitive

99 %
Expanscience’s eco-design
policy, Mustela Maternity baby skin, Mustela products are free
Stretch Marks Prevention of the following substances:
Oil is also friendly to Ammonium Lauryl Sulfate, Sodium
the environment through Lauryl Sulfate, p-Phenylenediamine
the end of its lifecycle, ingredients of natural origin and similar compounds,
thanks to a bottle that is in Mustela Maternity Stretch Phenoxyethanol, Paraben, Phthalates,
fully recyclable. Marks Prevention Oil BHA, Benzophenone, Ethylhexyl
Methoxycinnamate, Cyclotetrasiloxane,
Triclosan.
* The remaining 1% is attributable
to the need for an antioxidant
(tocopherol) to maintain the product’s
olfactory and general stability
over time. To find out more
View the Expanscience
natural products charter
at www.expanscience.com
 2015 ANNUAL REPORT E X PA NS C I E N C E 11

UNDE RSTA NDING

SK I N H EA LTH
F I RST A ND FO REMOST
A MATTE R O F SC I EN C E

WHAT IF FEELING GOOD

ABOUT YOURSELF STARTED
WITH HEALTHY SKIN? 
The discomfort caused by irritated skin
is proof: babies cry because their bottom
is sore, expectant mothers worry they’ll lose
their youthful skin forever after childbirth;
teenagers are embarrassed by the acne
invading their face, etc.
To preserve the health of their own skin or that
of their child, today’s consumers are becoming
more and more demanding. They’re looking
for the most natural products available:
IRRITATION, DRYNESS, ACNE, 77% of mothers of infants up to age 6 months
STRETCH MARKS... FROM BIRTH prefer to purchase products that have natural
ingredients(1). They want products
TO ADULTHOOD, SKIN CAN for their baby that are safe and enjoyable
BE SEVERELY TESTED FOR to use. For example, 61% of these mothers
pay close attention to the fragrance and scent
A VARIETY OF REASONS.
of the products they choose(1).
FACED WITH THESE ANNOYING For themselves, they value safety and
effectiveness, especially to remedy stretch marks
PROBLEMS, CONSUMERS
and skin tightness resulting from pregnancy.
WANT PRODUCTS Laboratoires Expanscience address all of these
FOR THEMSELVES AND concerns through a rigorous and ambitious
strategy of innovation coupled with research
THEIR FAMILIES THAT ARE SAFE, and development.
PLEASANT AND EFFECTIVE. – (1) IFOP 2015, Quantitative U&A Questionnaire on Babies, France

THE ABILITY TO FULFILL THAT

77 %
DESIRE REQUIRES A STRINGENT
AND THOROUGH RESEARCH
AND DEVELOPMENT PROCESS. OF MOTHERS OF INFANTS UP TO AGE
6 MONTHS PREFER TO PURCHASE
PRODUCTS WITH NATURAL INGREDIENTS.
12 U N D E R S TA N D I N G

SCIENTIFICALLY
PROVEN EFFICACY
UNDERSTANDING THE SKIN
OF PREGNANT WOMEN With regard to infants,
the EV.E.I.L.S.* studies, which
In order to preserve skin health, you must have previously looked at normal
first have an exceptionally detailed knowledge skin and the diaper area,
of the physiology of skin. That’s the aim of have now turned their attention
a new chapter in Expanscience’s EV.E.I.L.S* to other skin issues; in particular, the study
research program, which expanded in 2015 of normal skin is examining immature regulation
to include research on the skin of pregnant of the flow of water to the skin. In connection
women. These studies draw on substantial with the study, Mustela Hydra Bébé Body Lotion
human and technological resources was clinically shown to be effective on key markers
as well as partner research teams; coupled for hydration. At the same time, researchers used
with the recent discovery of the role played a new technology (triboacoustics) to define
by fibronectin, a protein, they’re providing and scientifically quantify skin softness, so as
a better understanding of the essential steps to demonstrate the product’s positive effects.
involved in the formation of stretch marks.
After ground-breaking research in which
cells from stretch-marked skin were
compared with cells from skin without Innovative strategies have
stretch marks, researchers were able to similarly been adopted
evaluate the level of fibronectin production. for developing two new active
With the help of these new models, ingredients intended for
they could then test the specific action the cosmetics industry
of different active ingredients. The results (see opposite). For the first,
were used to select the most effective active Pixalia, which targets
ingredient: galactoarabinan (derived from acne-prone skin, IR&D was
larch), chosen for its previously unknown able to demonstrate its effects during all four
ability to stimulate production of fibronectin phases of acne (inflammation, bacterial growth,
and reduce the onset of stretch marks. increase in sebum quantity, deterioration
*EValuation of Early Infant Life : the Skin of sebum quality), through in vitro testing
followed by clinical tests on volunteers.
For the second, Macaline, a new active ingredient
for the body, researchers turned to new

X 1.5
IN 2015, EXPANSCIENCE
investigation techniques that proved its efficacy
on cellulite (even embedded cellulite), drainage
and skin firmness.
INCREASED ITS R&D
INVESTMENT IN MUSTELA
BY 150%.
 2015 ANNUAL REPORT E X PA NS C I E N C E 13

MEETING THE CHALLENGE

OF NATURALNESS
To respond to international consumer demand
for products that are as natural as possible,
Innovation, Research & Development (IR&D)
has also focused its efforts on applying
Expanscience’s natural products charter, which
arose out of its Corporate Social Responsibility EACH EXPECTANT MOTHER
policy. For all new product development,
researchers follow strict specifications regarding
IS ALSO A WOMAN
natural products (see page 10). With its focus
The relaunch of Mustela Maternity has provided
on naturalness as a strategic asset in positioning
an opportunity to redefine the territory for the
its dermo-cosmetics brands, Expanscience will
product line, which is intended for new and
be expanding its communications to consumers
expectant mothers. In addition to a new name that
and healthcare professionals on the theme
is more emotional and less technical than “Mustela
of natural products in 2016.
9 months,” as well as more communicative product
names, the packaging has been changed to convey
more femininity and glamour, highlighting the
THE MUSTELA PRODUCT LINE STANDS
beauty of  a pregnant woman. The line clearly
OUT FOR ITS ETHICS, ITS SCIENCE,
addresses a need among women who take care
ITS INNOVATION AND ITS SUSTAINABILITY,
of themselves and want to preserve the beauty
ALL CONSISTENT WITH EXPANSCIENCE’S
CORPORATE SOCIAL RESPONSIBILITY POLICY. of their skin without harming their child.

TWO INNOVATIVE NEW

COSMETIC ACTIVE
INGREDIENTS
With the release of Pixalia and Macaline in 2015,
expanding a portfolio that already includes some
twenty cosmetic active ingredients, Expanscience
is on track to meet its goal of introducing two new
active ingredients each year. Pixalia, which made
its debut at the In-Cosmetics trade show, is unique
in its ability to treat acne in both teenagers and
DERMATOLOGICAL adult women. Sporting eco-designed packaging,
Pixalia is made from cleome gynandra, a plant
EFFICACY grown in Burkina Faso. With its threefold slimming,
AND NATURALNESS firming and draining action, Macaline signals
Expanscience’s emergence in the market for active
Intended for use in cleaning and caring ingredients for the body that go beyond treatment
for acne‑prone skin in teenagers and adults, for cellulite. Also marketed in eco-designed
the Boréade line of products from Noviderm packaging, Macaline has a formulation
contains, on average, 90% ingredients of based on maca, a plant already used in another
natural origin, and Boréade products are 100% active ingredient (Skinergium®) and sourced
eco-designed. Their formulations include from an eco-friendly supply chain in Peru.
quinoa peptides, a patented active ingredient
with soothing properties. Quinoa peptides
were developed in 2011 by researchers at
OUR AQUALICIA ACTIVE INGREDIENT
Expanscience IR&D after their anti-inflammatory RECEIVED THE GREEN INGREDIENT
properties were revealed in numerous studies AWARD GOLD MEDAL AT IN‑COSMETICS
and discoveries regarding their use for acne. 2015, IN HONOR OF ITS ECO-DESIGN
AND ACTIVE PROPERTIES.
 SOC I E T Y

OSTEOARTHRITIS
A COMPREHENSIVE
APPROACH
TO ENHANCING
MOBIL ITY

ADVOCATING A HOLISTIC
FORM OF TREATMENT
Although there is still no cure for osteoarthritis,
its effects can be mitigated and its progress
slowed to improve the quality of life
for patients and prevent the need for surgery or
WHEN OSTEOARTHRITIS STRIKES prostheses. The international recommendations
THE CARTILAGE IN THE HIP OR KNEE, on this topic, such as those of the Osteoarthritis
Research Society International (OARSI), are clear:
THE ACCOMPANYING PAIN CAN osteoarthritis requires comprehensive,
QUICKLY BECOME DISABLING. coordinated treatment, both pharmacological
and non-pharmacological, that enlists the help
THE RESULTING RISK OF ISOLATION
of physicians, pharmacists, physical therapists
AND SELF-EXCLUSION MAKES and patients themselves (lifestyle, nutrition,
physical exercise, etc.).
OSTEOARTHRITIS THE ELEVENTH
BIGGEST SOURCE OF DISABILITY
WORLDWIDE, ALL DISABILITIES
COMBINED(1). TO ENSURE
THAT PATIENTS CAN MAINTAIN
THEIR MOBILITY, EXPANSCIENCE
HAS BEEN PROMOTING A HOLISTIC
APPROACH TO TREATING
GIVEN RISING RATES
OSTEOARTHRITIS FOR MORE
OF OBESITY AND AGING
THAN 20 YEARS. POPULATIONS IN DEVELOPING
COUNTRIES, OSTEOARTHRITIS
- (1) The Lancet, 2012; vol. 380, no. 9859
HAS EMERGED AS A GLOBAL
DISEASE.
 2015 ANNUAL REPORT E X PA NS C I E N C E 15

DIGITAL TECHNOLOGY
FOR HOLISTIC
TREATMENT
As patients become increasingly connected
to the digital world, Expanscience is opting
for digital technology to provide enhanced support.

THE RISK OF A site devoted to Piasclédine 300

was introduced online in late 2015
DEMEDICALIZATION to give patients the information
IN FRANCE they need regarding their disease
and its treatment. The site will
www.piascledine.fr become available in different
The decision by France’s health authorities languages during 2016.
to stop the reimbursement of so-called
slow-acting anti-rheumatic drugs (SAARDs)
A customized support service
will have an inevitable effect on patient for osteoarthritis patients, featuring
comfort, especially for patients on a limited enhanced ergonomics and content
budget. If they are not reimbursed for their as of 2015 as well as a new
treatment, many of the five million patients community forum, will help more
than 10,000 registered patients
diagnosed with osteoarthritis(2) may choose
share information and advice.
to forgo future visits to the physician. www.arthrocoach.com A Spanish version of the site
A study conducted for Latin America will be introduced
With 20 years of in June 2015(3) indicates in late 2016.
that patients are
experience in the
unwilling to treat their With more than 40,000 visits each
comprehensive treatment osteoarthritis on their month, arthrolink.com is the
of osteoarthritis, own and are in critical preeminent website on
osteoarthritis for patients and
Expanscience is stepping need of advice and
healthcare professionals alike.
support from their In 2015 the site was expanded
up its commitment
medical practitioner. www.arthrolink.com to include a list of supplemental
to physicians and Over time, this health insurance policies that
pharmacists to ensure “demedicalization” could cover slow-acting anti-rheumatic
drugs (SAARDs).
that patient quality of life lead to increased rates
of surgery, as can be
is not adversely affected
observed in countries
by this decision where medical treatment
to demedicalize is less advanced.
treatment for - (2) Out of 10 million French people
affected; source: Livre blanc de l’arthrose
the disease. 2015.
- (3) WR Conseil study report for EXPANSCIENCE
TEAMING
Laboratoires Expanscience on the
impact of discontinuing reimbursement
for Piasclédine 300 (meetings with
groups of osteoarthritis patients
in Paris, Lille and Lyon). UP FOR RESEARCH
INTO OSTEOARTHRITIS

N
  °1
FROM MARCH TO DECEMBER 2015,
In December 2015, Expanscience was selected
to participate in and help fund the three-year ROAD
Project (Research on Osteo Arthritis Diseases),
a research program led by France’s Arthritis
PIASCLÉDINE 300 CEMENTED ITS STATUS
Foundation on chronic inflammatory rheumatic
AS THE MARKET LEADER BOTH IN UNITS
SOLD IN PHARMACIES AND IN diseases. Bringing together France’s seven largest
THE NUMBER OF PRESCRIPTIONS centers for basic research into osteoarthritis
WRITTEN BY GENERAL PRACTITIONERS (including laboratories at INSERM and CNRS),
AND RHEUMATOLOGISTS. the ROAD Project is designed to advance
Source: GERS Sell-Out, CSD-CAM. our knowledge of osteoarthritis and cell aging.
16 SOCIETY

EXPANDED OUTREACH
TO PATIENTS
Expanscience launched a major initiative to make
Piasclédine 300 more visible in pharmacies
and to enhance its packaging, its price
(now capped so as not to penalize patients)
and its presentation (now in packs of 30 capsules
rather than 15, more convenient for those
with chronic illness). In addition, a communications
campaign (web, print media, radio) was launched
targeting the general public to encourage medical
treatment for osteoarthritis. With the same goal
in mind, the company held a press conference
in September 2015. All of these actions have borne
fruit: at a time of declining sales overall, Piasclédine
300 has cemented its leadership in the market
for osteoarthritis treatment (see page 15).
A STRATEGIC DECISION
TO EMBRACE A NEW BUSINESS
A COMPLETE PORTFOLIO
MODEL FOR PIASCLÉDINE 300
FOR RHEUMATOLOGY
When Piasclédine 300 was delisted for
In 2016, Expanscience will be consolidating
reimbursement in France in March 2015,
this new business model with help from
Expanscience was quick to foresee the impact
the other products in its portfolio: Hyalgan
and responded by adopting and deploying
(injectable hyaluronic acid), Takadol (analgesic),
a new business model, dubbed OTX, based
Fixical (vitamin-calcium supplement)
on over-the-counter sales of the drug in
and Nabucox (non‑steroidal anti-inflammatory).
connection with a medical prescription.
And as a guarantee of medium-term growth,
The entire company mobilized to carry out this
Expanscience will be introducing a new drug
major change. To reduce the risk that treatment
in 2016 for first-line treatment of osteoporosis
for osteoarthritis would be removed from a
in menopausal women.
medical context - a trend that would harm
patient quality of life - the campaign focused
on highlighting the critical support provided
by healthcare professionals. Medical sales
representatives increased their efforts among
general practitioners and rheumatologists, and
also educated pharmacy personnel to give them
a better understanding of the disease.
OSTEOARTHRITIS IS FRANCE’S LEADING
CAUSE OF DISABILITY AMONG THOSE
AGED 40 OR OLDER AND THE SECOND
LEADING CAUSE OF VISITS TO GENERAL
PRACTITIONERS.
 MUS T EL A BÉBÉ MUS T EL A S UN CARE

1 2 3 VITAMIN BARRIER CREME VERY HIGH PROTECTION SUN SPRAY

MUS T ELAA
MUSTEL MUS
M U STT EL
ELAA
M AT ERNI
MATE TY
RNITÉ S T EL ATOPIIA
ST E L ATOP A

CRÉME PRÉVENTION VERGETURES BAUME RELIPIDANT STELATOPIA

STRETCH MARKS PREVENTION CREAM LIPID-REPLENISHING BALM
 MUS T EL A SUN CARE MUS T EL A BÉBÉ

Preser ve their skin Effica cy, safet y, ple asure

for the future. of use from bir th on.

VERY HIGH PROTECTION SUN LOTION • VERY HIGH MASSAGE OIL • PHYSIOBÉBÉ • CLEANSING MILK • HYDRA BÉBÉ
PROTECTION SUN SPRAY 200 ML • VERY HIGH PROTECTION BODY LOTION  •  DERMO CLEANSER  •  HYDRA BÉBÉ FACIAL
SUN SPRAY 300 ML • AFTER SUN SPRAY CREAM  •  1 2 3 VITAMIN BARRIER CREME

MUS T EL A S T EL ATOP IA MUS T EL A MAT ERNI T Y

A new life Preser ve the be aut y

for e czema-prone skin. of your skin with complet e
safet y for your baby.

BUST FIRMING SERUM  •  BODY FIRMING GEL

LIPID-REPLENISHING BALM  •  EMOLLIENT CREAM LIGHT LEGS GEL  •  SOOTHING MOISTURIZING BALM
CREAM CLEANSER  •  MILKY BATH OIL STRETCH MARKS PREVENTION OIL  •  STRETCH MARKS PREVENTION
CREAM  •  STRETCH MARKS RECOVERY SERUM
 As exp er ts in the t re a tme nt
of oste o ar thritis for more
than 20 y e ars, Labora toires
E xp anscie nc e provide
c omprehe nsi ve c are for
oste o ar thritis of the kne e
and hip and offer t re a tme nt
tha t is prove n effe c ti ve,
along with ser vic es
for da y -to -da y sup por t.

www.arthrocoach.com

www.arthrolink.com

www.piascledine.fr

RHE UM ATOLO GY

PIASCLÉDINE 300 MG
dr ug

Franc e’s to p - selling

slow - a c ting sy mptoma tic
anti- rheuma tic dr ug.
Source: GERS Sell-Out CMA 2015.

DERMATOLO GY DEN TAL CARE

PROCUTA Gé 20MG HYALUGEL GEL

drug me dic al devic e
 RHE UM ATOLO GY

An exhaustive, comprehensive line of produc ts

for the tre atment of osteoar thritis, calcium deficiency and pain.

dr ugs
FLEXEA 625 MG  •  FIXICAL VITAMIN D3, 1000 MG/800 UI  •  TAKADOL 100 MG
NABUCOX 1 G  •  PIASCLÉDINE 300 MG  •  HYALGAN 20 MG/2 ML

SOLD ONLY IN FR ANCE E XCEP T PIA SCLÉDINE 300 AND FLE XE A.

DEN TAL CARE DER MATOLO GY

A complete produc t line A wide se le c tion of therapeutic

for mouth pain, now expanded tre atments for mild to severe a cne
to include infant teething care in both adolescents and adults,
with Hyaluge l 1 st teeth. and a dr ug for the tre atment
of androgenetic alope cia in men.

me dic al devic es dr ugs

HYALUGEL SPRAY  •  HYALUGEL ADO  DOXYLIS Gé 100 MG • EFFIZINC 15 MG
HYALUGEL 1ST TEETH  •  HYALUGEL GEL  •  HYALUGEL MOUTHWASH PROCUTA 40 MG • FINHAIR Gé 1 MG

SOLD ONLY IN FR ANCE. SOLD ONLY IN FR ANCE.

 F E AT UR E

At the heart
of Laboratoires
Expanscience:
each one’s potential
makes everyone’s
success.

Beyond each individual’s talents and expertise, Expanscience employees share the same vision
and are bound together by the strong, unifying traits that constitute the company’s DNA: initiative,
creativity, performance, openness, solidarity, innovation, pride in belonging and responsibility. Each
day, these characteristics, defined in the wake of a 2015 workshop on Laboratoires Expanscience’s
identity, are concretely reflected in the way we work and in projects and actions dedicated to our
collective success, all to fulfill our common mission: protecting your health through innovation.

#PERFORMANCE #PRIDE #INNOVATION #RESPONSIBILITY

#CREATIVITY #INITIATIVE #SOLIDARITY #OPENNESS

22 F E AT U R E

# INNOVATION
LABORATOIRES EXPANSCIENCE ANTICIPATING THE NEEDS OF THE FUTURE
WERE ESTABLISHED IN 1950 With 87 patents registered in France and
843 patent applications filed worldwide,
FROM A COLLABORATION Expanscience has innovation in its blood!
BETWEEN A MANUFACTURER, Since 1950, Expanscience’s Research
& Development Center has been developing
PAUL BERTHOME, AND original formulations and new active principles
for maintaining health. To meet that objective,
A PHARMACIST, CLAUDE
the company also creates innovative services
GUILLON. THEIR TALENT WAS for lending support to consumers, patients
and healthcare professionals.
TO CREATE A MINDSET AND
AN ENTREPRENEURIAL SPIRIT
“In order to introduce new dermo-cosmetics products
THAT CONTINUE TO DRIVE and respond to the needs of consumers, we need to adopt
new technology and conduct innovative research, both as a
THE WORKFORCE EVEN TODAY. preliminary step, to take our knowledge of the skin even further,
and during the actual development phase, through the use
MORE THAN SIXTY YEARS LATER, of new in vitro methods, and the clinical phase.”

EXPANSCIENCE BRINGS NEARLY

1,000 EMPLOYEES TOGETHER FRANCK MENU
Cosmetic Innovation
BEHIND A SHARED CULTURE and Development Manager

AND IDENTITY.

# SOL IDARITY
STRENGTHENING THE TIES
THAT BIND US
Commitment to the community is an integral part
of Expanscience, reflected in the sponsorship
activities led by the Fondation Mustela for more
than three decades and the company’s proactive
Corporate Social Responsibility policy, established
in 2004. Consistent with that commitment, since
2015 Expanscience has been offering its workforce
the opportunity to support projects by two
humanitarian organizations, Care France and
Action Enfance, through micro-donations,
in a show of employer/employee solidarity.
Employees who wish to participate can
lend support to either organization through
a monthly micro-donation deducted from
their salary that is matched by Expanscience.

Fondation Mouvement
pour les Villages d’Enfants
 2015 ANNUAL REPORT E X PA NS C I E N C E 23

# OPENNESS
ADAPTING TO NEW HORIZONS
In order to innovate, improve our procedures
or capture new markets, Expanscience
employees need to explore new paths.
This open-minded attitude played a critical
role during the initial months of Expanscience’s
new Russian subsidiary, tasked with raising
the Mustela brand’s profile in the various
regions of the country.

“We visited numerous regional events and conventions

for pediatricians to talk about the discoveries from
our EV.E.I.L.S research program on infant skin from
birth, and we explained exactly how and why we give
priority to ingredients of natural origin in our product
formulations. At the same time, in a country where
mothers are very careful about the products they
choose for their babies, we visited numerous ‘schools
for mothers’ where we could meet with them one on
one. The reception we received from both healthcare
professionals and mothers suggests that there’s
a very bright future for sales of Mustela in Russia.”

ARINA BAYBURTYAN
General Manager Russia
# RESPONSIBIL ITY
TAKING ACTION ON BEHALF
OF SUSTAINABLE GROWTH
For more than a decade, Expanscience has been
developing an ambitious – and widely hailed –
policy of social and environmental responsibility
that not only generates value for the company’s
target audience but serves to differentiate
# CREATIVITY Expanscience brands (see page 30). Taking care
of young children and new and expectant mothers
also means protecting their environment, so
ENSURING THAT EVERYONE Mustela acts in every way possible to minimize
CAN SPUR PROGRESS the environmental impact of its products at each
Creative companies are more agile and innovative. stage of their lifecycle.
That’s why Expanscience is developing a culture
of innovation that fosters creativity among its
“The eco-design we use for Mustela products, which encompasses
employees. With that goal in mind, in 2007
their entire lifecycle, addresses two of the primary expectations
the company created Graine d’ID, a system among young mothers: naturalness and safety. As a laboratory,
of participatory innovation that lets employees we feel obligated to think about what will happen at the end
propose ideas on their own or in response of each product’s life. So we take numerous concrete steps
to specific concerns. Two hundred ideas to educate consumers about proper sorting procedures
in the bathroom. In my view, that’s an essential part of being
were submitted during 2015 in a variety of areas
a responsible dermo-cosmetics brand, especially one focused
(international development, improvements on a period of life that’s so important for the future.”
in day-to-day procedures, production,
commercial development of innovations).
After being evaluated by special committees,
these ideas were subsequently implemented SYBILLE FOING
within Expanscience and will help ensure Mustela France
our success in the future! Marketing Director
 # PRIDE
LENDING MEANING TO ALL OUR ACTIONS
Over the years Expanscience has been honored
on numerous occasions for the ongoing efforts
of its employees, who make a daily commitment
to responsible economic growth, more virtuous
products and helpful support services
for its customers and healthcare professionals.
This recognition is a source of pride, credibility,
legitimacy and progress for a company that
has always been eager for transparency regarding
its offerings and its CSR policy. The past year
was especially fruitful in this regard. Expanscience
won awards for its CSR policy (LEEM(1) Award,
the Green Ingredient Award for its cosmetic active
ingredient Aqualicia, Responsible SME Award),
for its services on behalf of patients and
consumers (arthrocoach.com, “Mustela & me”),
and for its products (2015 Family Brand Award for
Mustela in the “Pregnant woman beauty products”
# PE RFORMANCE and “Beauty & care products for children” categories;
123 Vitamin Barrier Cream voted 2016 product
RESPONSIBLE, PRODUCTIVE GROWTH of the year).
For Expanscience, growth is inseparable (1) LEEM: Les Entreprises du Médicament, a trade organization for the French
pharmaceutical industry.
from the desire to provide consumers
and patients with effective, safe solutions
that help to improve both their health
and their quality of life. That approach,
which has guided the group’s international
expansion, can be seen in the treatment
for osteoarthritis, an increasingly prevalent
disease worldwide. In the nearly forty
countries where Piasclédine 300 is CONCRETE STEPS
distributed, our local workforce offers
comprehensive treatment options for
TO IMPROVE WORKPLACE
osteoarthritis patients and provides support QUALITY OF LIFE
to healthcare professionals – as in Chile,
where the drug has consolidated its position Convinced of the strong link between
as the market’s top‑selling product. professional well-being and individual
and collective performance, Expanscience
maintains a workplace quality of life program
“Chile is a booming market (thanks to economic growth and for its employees. In line with the corporate
high rates of osteoarthritis), but also a very competitive one.
social responsibility policy, the program
That’s why our local sales partner has an extensive team of
medical sales representatives who promote Piasclédine 300 aims to improve workplace practices
among a wide range of healthcare professionals (primarily through concrete actions and services:
general practitioners, rheumatologists and orthopedic
surgeons). After six years on the market, our specialty is now
the leading product in its category. We work with our partner
AGREEMENT ON GENDER EQUALITY
to find and deploy new digital and marketing tools, to ensure AND PAY EQUITY
we’re constantly more knowledgeable about prescribers
and their needs.” PROGRAMS TO PROMOTE
A WORK-LIFE BALANCE

PERFORMANCE CYCLE WITH THREE

EMPLOYEE/MANAGER INTERVIEWS EACH YEAR

HEALTH WEEK
ROMAIN RENARD
Area Sales Manager – DISABILITY ACTION PLAN
Latin America
EMPLOYEE SATISFACTION ASSESSMENT
VIA INTERNAL SURVEY

AND MORE
 E X PA NS C I E N C E 25

THE EXPANSCIENCE
#PRIDE IDENTITY
AT THE HEART
OF ITS NEW
“EMPLOYER BRAND”

In October 2015, Expanscience unveiled

its new human resources communications
campaign. Designed to encourage employee
loyalty, create a cohesive workforce
# INITIATIVE and attract candidates for employment,
the campaign sums up the company’s
identity with an explicit tagline: each
EXPANDING THE POSSIBILITIES one’s potential makes everyone’s success.
To illustrate that belief and demonstrate
For Expanscience, there’s more
the attention Expanscience gives to its men
to preserving health than offering safe
and women, the campaign describes
and effective products and treatments.
the network of talents to which every
To demonstrate that conviction, the
employee contributes and the strong,
company develops innovative services
unifying traits that bind the workforce
that provide support to consumers,
together: initiative, creativity, performance,
patients and healthcare professionals –
openness, solidarity, innovation, pride
services like arthrocoach.com,
in belonging and responsibility.
a personalized digital coaching resource
for people suffering from osteoarthritis.

“Arthrocoach.com works in tandem with physicians

by serving as a companion that patients can use between visits
to the rheumatologist. The tool helps patients progress at their
own pace by coaching them on their physical activity
and nutrition. Its monitoring curves give them a clearer picture
of their progress and the improvements they still need to make.
Available for computer, tablet or smartphone, the tool was
developed in partnership with rheumatologists and experts
in physical and nutritional coaching. A Spanish version for Latin
America will be introduced in the near future.”

LAURENCE MARCHAL
Digital Manager
 2266 R E P O R TA
I NGGE

RE PORT ING

IR&D AND PRODUCTION

BEHIND
THE SCENES
IN ÉPERNON
RESPONDING TO TODAY’S CONSUMER
DEMAND AND ANTICIPATING THE DEMAND
OF THE FUTURE: THAT’S THE TWOFOLD
RESPONSIBILITY OF OUR SITE IN
ÉPERNON, HOME TO THE IR&D CENTER
AND PRODUCTION. HERE’S A LOOK AT
A KEY RESOURCE FOR EXPANSCIENCE’S
GROWTH, A SITE THAT BOASTS A WIDE
RANGE OF EXPERTISE AND CONSTANTLY
ADAPTS TO PROVIDE SUPPORT
FOR THE COMPANY’S STRATEGY.
 2015 ANNUAL REPORT E X PA NS C I E N C E 27

Challenge
met! An intense year
for the IR&D center
The Expanscience production site has What with the EV.E.I.L.S. studies on infant skin,
successfully kept pace with growing research into the skin of pregnant women,
demand in its international markets. multiple new Mustela products developed,
Production capacity for Piasclédine 300, the launch of two new cosmetic active
Expanscience’s flagship anti-rheumatic ingredients, expanded scientific communication
drug, rose to a new high in 2015 of more and more, the IR&D center had an exceptionally
than 420 million capsules. Production in busy year in 2015. It also invested in the future.
dermo‑cosmetics climbed to record levels In addition to hiring new employees, the center
as well, with 22 million Mustela bottles acquired innovative new analytical technology
produced in 2015. These accomplishments for generating more sensitive and specific
are the result of employees mobilizing data. It lets researchers characterize in detail
behind the performance plan launched in 2014 the chemical structures that make up each
(see page 29). The outlook for 2016 is just as product (raw materials, active ingredients,
promising. For example, a new production finished products) so as to provide an even
line for dermo-cosmetics that came online stronger guarantee of their quality and safety.
at the start of the year will produce 10 million
additional Mustela products in tube format.

A key regional
player
Based in Épernon near Paris since 1957,

1 = 3
Expanscience is also notable for
the role it plays in local economic development.
An economic impact study conducted by
1 JOB AT EXPANSCIENCE an independent organization* offers proof: the
CREATES OR MAINTAINS Épernon site alone accounts for 11% of all jobs
3 ADDITIONAL JOBS in the pharmaceutical, cosmetics and chemical
IN THE FRENCH
sectors in the surrounding département of
ECONOMY
Eure-et-Loir. To uphold its regional role and
responsibilities, Expanscience maintains an
ongoing dialogue with its local stakeholders.
* Local Footprint methodology, Utopies.

€50 M
IN INDUSTRIAL
A NEW INSTALLATION
OFFERING A THREEFOLD BENEFIT
INVESTMENT In 2015 the Épernon site unveiled a new facility
OVER THE NEXT FIVE YEARS devoted to molecular distillation, a process used to
AT THE ÉPERNON SITE produce active ingredients of natural origin, including
the Avocado oil and Soybean oil Unsaponifiables*
used in the composition of Piasclédine 300 and the
cosmetic active ingredients derived from sunflower

66 M
UNITS PRODUCED IN 2015,
oil. This equipment will double the site’s production
capacity and drastically reduce its electricity use
and water consumption (the latter by more than
10,000 m3 annually), while slashing production costs.
INCLUDING 44 MILLION
* ASU
DERMO‑COSMETICS
UNITS AND 22 MILLION
PHARMACEUTICAL UNITS
28 REPORTING

01

02 03

01 02 03
COORDINATING AND MOBILIZING A POLICY HIGH-RESOLUTION ANALYSES
TO ENSURE SUCCESS OF CONTINUOUS IMPROVEMENT
“My colleagues and I develop analytical
“I oversee the production unit for active “On a day-to-day basis, I’m responsible methods covering the raw material up
principles of natural origin, such as those for checking the physical-chemical analytical to the finished product that are then
used to produce our Piasclédine 300 drug. reports for the raw materials and the used by the quality control staff during
I’m involved in multidisciplinary teams, pharmaceutical and cosmetics products that the production process. For that task,
with members drawn from the support enter and leave our manufacturing site. we now have cutting-edge analytical
functions, that manage and carry out One of the major projects in our Performance technology in the form of high-resolution
projects for improvement. In addition Plan is to improve how the inspection laboratory mass spectrometry, which will enhance our
to coordinating and monitoring activity is organized. For my part, I’m working with analytical resources and expertise for all
in a workshop that operates 24 hours the Innovation Research & Development Center types of products, including raw materials,
a day, 7 days a week, 315 days a year, to review some of our inspection techniques, active ingredients and finished products.
my job is to coordinate, mobilize and in order to make them faster and more accurate Thanks to this new investment, we can
empower our employees. That requires or to bring them in line with new, more efficient be even more effective and ensure even
a lot of listening, communication and technology. Our goal is to see improvement greater quality and safety in the products
support to ensure we can successfully every day in the quality of the products we bring to the market.”
tackle the numerous challenges we face.” we provide to customers.”

NELLY LEGOUT /
STÉPHANE GENÈVE / SONIA WASIELEWSKI / ANALYTICAL DEVELOPMENT
CHEMICAL UNIT MANAGER PHYSICO-CHEMISTRY TECHNICAL LEADER PROJECT LEADER, INNOVATION,
- INDUSTRIAL QUALITY CONTROL RESEARCH & DEVELOPMENT CENTER
 2015 ANNUAL REPORT E X PA NS C I E N C E 29

04 04
AMERICAN-STYLE QUALITY

“Our Mustela Bébé 123 Vitamin Barrier Cream

is officially classified as a drug in the United
States. As a result, it needed to comply with
the American pharmaceutical guidelines
in order to be sold in the US market. That’s
what the US regulatory agency, the Food and
Drug Administration, came to verify as part
of an inspection at the Épernon site. That
inspection, which involved several different
teams at the site, offered an opportunity to
review our procedures and strengthen our
05 quality policy even further, by applying certain
pharmaceutical requirements to our cosmetics
products. I’m proud to have helped meet that
challenge as a Quality Products Executive.”

CATHERINE GOSSET /
QUALITY PRODUCTS EXECUTIVE,
INDUSTRIAL QUALITY

05
SHORTER PRODUCTION TIMES
“As an equipment operator on the cosmetic
bottles line for 16 years, I participated
in the Performance Plan project to see how
we could improve production times.
For six months, I worked alongside several

06
of my colleagues to observe and analyze
the various steps for changing bottle formats
on the line, the machine configurations,
the factors that contribute to breakdowns
and so on. We reported on the problems
we found and suggested improvements.
Once new standards and handling times had
been defined, we looked at how they would
actually work on the ground, to ensure they
were consistent and applicable for day‑to‑day
operations. Ultimately we made a lot of
progress, and I felt that this process was a
real acknowledgement of my experience.”

PATRICK BAUDÉ /
EQUIPMENT OPERATOR,
DERMO-COSMETICS PRODUCTION UNIT

06
EXTREMELY DEMANDING TESTS
“In order to comply with the formulation
specification for Mustela Maternity Stretch
Marks Prevention Oil – which calls for safety,
efficacy, pleasure in use, naturalness and
respect for people and the environment
– we tested quite a large number of
plant oils. After various stability tests and
toxicology studies, we selected five oils:
avocado, pomegranate, sunflower, musk
rose and baobab. We eventually succeeded
in developing an oil for preventing stretch
marks that is 99% of natural origin, that
doesn’t leave a greasy film and that offers
remarkable olfactory stability. I’m very
proud that it received a Victoires de
la Beauté consumer award in France.”

TEDDY DUPUIS /
FORMULATOR, INNOVATION,
RESEARCH & DEVELOPMENT CENTER
30 CSR SAGA

Corporate
Social
SAGA Responsibility:
A DECADE
OF ACTIONS TAKEN
AND COMMITMENTS MET

2O1O FOR MORE THAN 10 YEARS, EXPANSCIENCE

A SET OF CORE CSR HAS MAINTAINED A DEMANDING CORPORATE
COMMITMENTS FOR THE YEAR
2015 IS FORMALLY DEFINED SOCIAL RESPONSIBILITY POLICY TO IMPROVE
THE DAILY LIVES OF ITS PATIENTS AND CONSUMERS,

2O11 ENHANCE ITS VALUE TO SOCIETY AND REDUCE

ITS IMPACT ON THE ENVIRONMENT. IN THE PAST
EXPANSCIENCE BECOMES
A MEMBER OF THE UNION FIVE YEARS, THIS GOAL HAS BEEN FORMALLY LAID
FOR ETHICAL BIOTRADE (UEBT)
OUT IN AMBITIOUS OBJECTIVES THAT THE COMPANY

2O12
IS PROUD TO HAVE MET, THANKS TO A DIALOGUE
WITH ITS STAKEHOLDERS AND ITS EFFORTS TO
ISO 14001 CERTIFICATION
OF THE ÉPERNON SITE MOBILIZE NEARLY 1,000 EMPLOYEES WORLDWIDE.

2O13
EXPANSCIENCE BECOMES
THE FIRST PHARMACEUTICAL
AND DERMO-COSMETICS
LABORATORY WHOSE
CONTRIBUTION TO SUSTAINABLE
DEVELOPMENT IS RECOGNIZED
AS EXEMPLARY BY AFAQ 26000

2O14
EXPANSCIENCE CELEBRATES
10 YEARS OF MEMBERSHIP
IN THE UNITED NATIONS GLOBAL
COMPACT, THE STARTING POINT
FOR ITS COMMITMENT TO
A PROACTIVE CSR POLICY

2O15
CHALLENGE MET! EXPANSCIENCE
FULFILLS THE COMMITMENTS
SET IN 2010*
* Except for the targets
for lower energy consumption
and waste production
at the Épernon site

2O16
EXPANSCIENCE LAUNCHES
THE BETTER LIVING PROGRAM:
ITS PROGRAM OF COMMITMENTS
FOR 2020 TO HELP MAKE
LIFE BETTER IN ALL
OF ITS COMMUNITIES
 2015 ANNUAL REPORT E X PA NS C I E N C E 31

PRODUCTS THAT ARE

FRIENDLIER
TO THE ENVIRONMENT

2015 objective:
RESPONSIBLE SUPPLY Establish an action plan to reduce
the environmental impact
LINES FOR PLANT of our principal drug
RAW MATERIALS
FULFILLED

2015 objective: Expanscience will Piasclédine 300, an Expanscience drug used to treat
have implemented a CSR action plan osteoarthritis, was subjected to a lifecycle analysis
for 100% of its plant supply chains to identify its environmental impact. Since the drying
process used for avocado, the key ingredient in
FULFILLED Piasclédine 300, is the largest contributor to the
product’s environmental impact, Expanscience
In each of its 19 supply chains for the plant raw defined an action plan with its partner avocado
materials that form the basis of the pharmaceutical producers. In Peru, for example, the plan helped
active ingredients and certain cosmetic active to reduce natural gas consumption by 18%**.
ingredients used in its products, Expanscience In Épernon, the Avocado oil and Soybean oil
has established an action plan to ensure respect Unsaponifiables used to create the drug are then
for biodiversity and compliance with fair trade produced in a facility built to High Environmental
principles. This initiative has been recognized Quality (HEQ) standards. An effluent pretreatment
by the Union for Ethical BioTrade (UEBT) plant has been installed as well. Moreover, by
since 2011. Expanscience’s procurement policy packaging Piasclédine 300 in packs of 30 capsules
won additional plaudits in 2015: Aqualicia, rather than 15, the volume of paper and cardboard
an acacia-derived cosmetic active ingredient, used for the product has been reduced.
was honored with a Green Ingredient Award
** Between 2010 and 2015, per 100 units produced
for its composition and the sustainability of its
development process. In sourcing its acacia from
Burkina Faso, Expanscience offers economic
opportunities to a group of female harvesters
and responds to local concerns regarding 2015 objective: All new Mustela
biodiversity protection and human development. and Noviderm dermo-cosmetics
products will be eco-designed in 2015

FULFILLED

“As of 2014, all new dermo-cosmetics products

are subjected to our evaluation tool dubbed EENOE
(from the French acronym for “Together Let’s
Eco‑Design Our Expanscience Products”). We use
the tool to gauge the effort that went into developing

455
a new dermo-cosmetics product, with a view
to reducing its environmental impact at each stage
of its lifecycle. This assessment is performed on
the basis of qualitative and/or quantitative data on
EMPLOYEES TRAINED
five factors: raw materials and formulation, primary
IN EXPANSCIENCE’S CSR
and secondary packaging, tertiary packaging,
POLICY IN 2015 USING THE industrial manufacture, use. To qualify as eco-
CSR PASSPORT: A TRAINING designed, a new product must outperform its
PROGRAM (INFORMATION, reference product by obtaining a higher score both
COLLABORATIVE WORKSHOP, overall and on at least one of the five factors.
GAMES AND MORE) To give one example, all of the products in the Mustela
DESIGNED TO PROMOTE Bébé range relaunched in 2014 met that standard.”
A FULLER UNDERSTANDING Marie-Noëlle Joinville
OF THE POLICY Cosmetic Innovation and Eco-Design Manager

12
AWARDS BESTOWED
ON EXPANSCIENCE’S
CSR POLICY
SINCE 2012
 36 SAGA RSE

EXPANDED SOCIAL
RESPONSIBILITY

2015 objective: introduce

an employee skills development
policy to promote professional
development and improve
the company’s performance

FULFILLED

ENVIRONMENTAL “Since 2010, our human resources policy

IMPACT REDUCED, has made professional development a priority.
Each employee now has three annual meetings
OUR RESOURCES PRESERVED with his or her manager (annual interview, evaluation
interview, career development interview).
2015 objective: Reduce natural gas, We’ve also established a monthly meeting with
electricity and water consumption all managers so they can talk to their teams about
and waste production at the Épernon the company’s direction and key projects. Moreover,
site (IR&D and production) by 20% we’ve led some major initiatives regarding mobility
and qualifications. For example, medical sales
PARTIALLY FULFILLED assistants have had the chance to acquire
the skills to become medical sales representatives,
“Between 2010 and 2015, our water consumption per while machine operators received 70 hours
100 units produced was cut by 22% and our natural of training to obtain a professional certificate
gas consumption by 25%, thanks to upgrades and of qualification.”
improvements (boiler insulation, burner replacement
Fanny Debbi, Human Resources Director
and so on). We reduced electricity consumption by
16% by replacing compressors and optimizing lighting
and climate control in the production units. These
water and energy savings will increase in 2016 with 2015 objective: Complete
the new molecular distillation facility (see page 27). the Workplace Quality of Life program
Waste production, meanwhile, increased by 38.5%
over the period. Seventy percent of the waste
FULFILLED
produced consists of the sludge generated when
tanks are washed; if this rinse water is excluded,
Numerous actions have been taken with regard
waste production fell by 19%.
to workplace quality of life, including a campaign
The commissioning of a second pretreatment
to promote work/life balance, enhanced medical
plant in late 2016 will reduce our volumes
coverage, a Health Week event held annually
of waste to a very substantial degree.”
since 2013 for employees in France and abroad,
Didier Levêque, Site Director and an employee satisfaction survey conducted
since 2012. This policy has yielded dividends:
in France, Expanscience was awarded the 2015
2015 objective: Reduce
Victoire d’Or du Capital Humain award in the
greenhouse-gas emissions by 20%
pharmaceutical industry, given to companies
with the best HR policies.
FULFILLED

Our efforts have been successful!

At equivalent production levels,
our greenhouse-gas emissions are 25%
lower than those of 2008***.
*** At equivalent production levels, excluding sourcing
of raw materials and subsidiaries’ distribution activities.

-20.5 %
OUR REDUCTION OF NATURAL
GAS AND ELECTRICITY
CONSUMPTION COMBINED
BETWEEN 2010 AND 2015
AT THE ÉPERNON SITE,
PER 100 UNITS PRODUCED
 2015 ANNUAL REPORT E X PA NS C I E N C E 33

Corporate
Social
Responsibility INNOVATE IN A RESPONSIBLE
AND COLLABORATIVE WAY

What
This new road map is designed to make corporate social
responsibility even more integral to the Expanscience organization,
so that the company becomes a greater contributor to society

new goals
and anticipates community needs more effectively. Building
on the commitments pledged for 2010-2015, the Better Living
Program contains new objectives drafted jointly by Expanscience
and its internal and external communities.

for 2020? PROGRESS WITH OUR COMMUNITIES

Laboratoires Expanscience are also committed to expanding
INCREASINGLY GLOBAL OPERATIONS, CHANGING their business responsibly, both in France and worldwide, by
BUSINESS STRATEGIES, NEW STAKEHOLDER EXPECTATIONS consistently combining progress with ethics in developing their
FOR BUSINESSES, NEW ENVIRONMENTAL AND SOCIAL innovations. Expanscience hopes to meet these challenges while
making progress alongside its communities.
CONCERNS... ON THE STRENGTH OF A CSR POLICY
DEFINED MORE THAN A DECADE AGO, EXPANSCIENCE
IS TARGETING NEW MILESTONES WITH ITS PROGRAM
OF COMMITMENTS FOR 2020. ITS GOAL: TO HELP
IMPROVE LIVES IN EACH OF ITS COMMUNITIES (PATIENTS,
TAKE CARE OF OUR CUSTOMERS
CONSUMERS, EMPLOYEES) BETWEEN NOW AND 2020,
AND OF THEIR ENVIRONMENTS
AS PART OF THE LABORATOIRES EXPANSCIENCE
As its way of caring for its customers and their environment,
“BETTER LIVING PROGRAM”. Laboratoires Expanscience and their brands pledge to provide
products that are more responsible throughout their lifecycle,
and to creating solutions that enhance treatment and aid
prevention in the areas of skin health and osteoarthritis.
34 HERE & T HERE

H E RE & THE RE
A ST RONG E R
PRESENCE
ON 5
CONT INE NTS

IN 2015 EXPANSCIENCE
REACHED A SYMBOLIC
AND DECISIVE MILESTONE. Our performance of the past year
FOR THE FIRST TIME,
offers proof: Expanscience is on track
to meet its objective for 2020
ITS INTERNATIONAL of generating 75% of its turnover
TURNOVER EXCEEDED ITS from international markets.
TURNOVER IN FRANCE, The share of sales outside France has risen from
WHICH ALSO INCREASED. 44.9% in 2013 to 46.1% in 2014 and 51.3% in 2015.
The acceleration over the past year can be attributed
HERE’S A LOOK BACK
to the export success of Expanscience’s business lines
AT HOW VARIOUS and the performance of its subsidiaries.
PRODUCTS PERFORMED
The dermo-cosmetics business built on its past
IN THE PRINCIPAL achievements and captured new ground, thanks to
COUNTRIES WHERE the relaunch of Mustela Maternity, the success of
123 Vitamin Barrier Cream and the bestsellers in the
THEY ARE MARKETED.
Mustela Bébé line (Dermo-Cleansing, Hydra Bébé,
etc.). The rheumatology business logged an impressive
increase in sales volume for Piasclédine 300 outside
France (up 20%), on the strength of organic growth
and consolidation of the market share first captured
in 2014.
Lastly, the cosmetic active ingredients and dermatology
business lines (see page 38) saw turnover increase
by 15% and 5% respectively.

51.3 % 75 % 60 % 15 %

SHARE OF EXPANSCIENCE OF TURNOVER FROM SHARE OF MUSTELA GROWTH IN
TURNOVER INTERNATIONAL SALES. TURNOVER FROM PIASCLÉDINE 300
GENERATED OUTSIDE THAT’S THE GOAL INTERNATIONAL SALES BY VOLUME
FRANCE IN 2015 EXPANSCIENCE HAS SET SALES IN 2015 IN 2015
FOR 2020
UNDISPUTED
LEADERSHIP
POSITIONS EUROPE
IN EUROPE

To cement Mustela’s position as

Europe’s top-selling pharmacy
brand, Expanscience opened a subsidiary in Russia
in June 2015. This country offers significant growth
potential in the market for dermo-cosmetics baby
products. Middle-class mothers in Russia are willing
to spend more on quality infant care products. In where Mustela Bébé has the highest market share
its first months of operation, the new subsidiary of any country in the world (73%), the subsidiary
has been working on getting its products into retail changed its logistics partner so as to improve the
outlets and on the brand’s name recognition among quality of service provided to customers in 2016.
healthcare professionals. Initial results for 2016
suggest Expanscience is on track to fulfill its goal In France, thanks in particular to 123 Vitamin Barrier
of making Mustela Russia’s top-selling Premium Cream, reintroduced in 2014, Mustela Bébé increased
infant brand. Our subsidiary in Poland has captured its market share by two points, strengthening
success by focusing on its launch of Mustela its position as the market leader well ahead of its
Maternity in a market dominated by local brands. nearest rival (all distribution channels combined).
The Turkish subsidiary, established in 2013, delivered Mustela Maternity, meanwhile, garnered an excellent
on the promise of that booming market by gaining reception in pharmacies and logged substantial
new market share. growth in the stretch marks segment (with market
share up nine points). In 2016 Mustela plans to
Western Europe posted an impressive performance consolidate its market position in care products
as well, thanks to the especially warm reception for infants, children, mothers and mothers-to-be.
given to the new Mustela Maternity line and the The brand will be expanding its digital and media
Mustela Bébé line, which has cemented its leadership promotions and increasing its visibility at points of
position (with market share of 50% to 70% in some sale. In addition, it will be presenting Expanscience’s
countries). Italy is a perfect example of this sales R&D findings on atopic skin to healthcare professionals.
momentum, with Mustela Bébé vaulting to the top
of the market in pharmacy sales. The Portuguese PIASCLÉDINE 300 During 2015 Piasclédine 300
and Spanish subsidiaries have likewise seen steady posted strong results
growth, despite the economic crisis. In Belgium, in the six Central European countries where it is
marketed, particularly in Poland, the Czech Republic
and Slovakia. In Russia the product was buffeted by the
impact of regional geopolitics and the economic crisis.
Nonetheless, positive momentum had returned by the
end of the year, prompting hopes for a recovery in 2016.
France’s decision in March to discontinue reimbursement
for slow-acting symptomatic anti-rheumatic drugs
weighed on sales of Piasclédine 300. But with
Expanscience’s adoption of a new business model
for its drug (see page 16), Piasclédine 300 has
reasserted its market leadership, increasing its lead
over its nearest competitor and gaining market share.
36 HERE & T HERE

AME RICAS

STRONG MOMENTUM
IN NORTH AND
SOUTH AMERICA

PIASCLÉDINE 300 Given the strong potential

in Latin America,
Expanscience has hired a special regional sales
manager in Brazil, tasked with boosting sales of
Piasclédine 300 on the continent. The product
has performed impressively in its two major
markets, Chile (where it ranks first in market share)
and Argentina. In Mexico, 2015 ended with a strong
sales performance (a 10% increase in market
share), despite an exceptionally competitive market.
And in preparation for the launch of Piasclédine 300
in the Brazilian market in Spring 2016, Expanscience
has selected a partner to operate in the country,
which represents the biggest market for SAARDs*
in South America.
* Slow-Action Symptomatic Anti-Rheumatic Drugs The 2015 opening of a subsidiary in
Canada, a country ranked among the
top 10 worldwide in purchasing power, has already
produced results. Mustela reported 40% growth
in Canadian sales during 2015, thanks to a sharp
acceleration in the number of pharmacies stocking
Mustela products, plus targeted trade campaigns
that focused on the quality of the products.
The Mexican subsidiary, for its part, returned to a path
of growth in 2015 after reintegrating several support
functions that had previously been outsourced.
Its Brazilian counterpart, established in 2013, enjoyed
steady growth by expanding into Brazil’s southern states
and anticipates a promising year in 2016, thanks to the
late-2015 launch of 123 Vitamin Barrier Cream in the
world’s second largest market for the category. And
in the United States, Mustela has maintained its position
in the face of new rivals that have invested heavily in
the media and at retail outlets.
 2015 ANNUAL REPORT E X PA NS C I E N C E 37

AFRICA AND
THE MIDDLE EAST:
GROWTH DRIVERS
IN THE MAKING

PIASCLÉDINE 300 In September 2015,

Piasclédine 300 made
a successful debut in the South African market,
suggesting a positive outlook for 2016. In North
Africa, sales continued to improve in Morocco
– a long-standing market for Piasclédine – but
were hampered in Algeria by the government’s
decision to follow the path of its French
counterpart in discontinuing reimbursement
for anti-rheumatic drugs. The Middle East
posted a solid sales performance in the three
major countries managed by our Cairo-based
partner: Eg ypt, Saudi Arabia and Iran.

After tripling its turnover on the

African continent over the past four
OCEANIA years, Mustela continued to see strong growth
in 2015, notably in Algeria, Morocco and Ivory Coast.
In 2016 the brand will be targeting South Africa, the
only major African country where it has not been
available, in conjunction with a local partner. In
addition, to oversee growth in the dermo-cosmetics
business in the Middle East – a region that offers high
potential, given the number of births, the extensive
use of medical care and elevated purchasing power
– Expanscience has opened an office in Dubai.
OCEANIA:
HIGH AMBITIONS
IN AUSTRALIA
With 23.1 million inhabitants, more than 300,000
births annually and a growing economy for more
than 20 years, Australia offers strong potential for
Mustela. With that in mind, Expanscience established a
subsidiary in the country in 2014 to boost sales,
which had been handled by a distributor for the
previous decade. In 2015 the subsidiary continued to
anchor its standing in the market by making the brand AFRICA
more visible, with the aim of capturing 50% of the
Premium market for infant skin care in pharmacies
over the coming years. The year was also marked by
a first for the subsidiary: The science committee for
the Annual Scientific Meeting, a major dermatology
conference in Australia, invited Expanscience
to present the results of its EV.E.I.L.S. research
program on infant and child skin.
 SUSTAINED GROWTH
FOR COSMETIC ACTIVE
INGREDIENTS
Expanscience’s cosmetic active ingredients business,
which markets cosmetic active ingredients
and sensory ingredients in about fifteen countries,
tallied double-digit growth in 2015, notably thanks
AS I A to Aqualicia, a cosmetic active ingredient
for cell hydration that was introduced in 2014.
In addition to performing exceptionally well
in France, its primary market, the business
has expanded its sales in China, where Premium
active ingredients are in growing demand among
local firms seeking to move upmarket.

Soline, a moisturizing active ingredient with soothing

and lipid-replenishing properties, has had a banner
STRENGTHENING year in the United States thanks to the successful
launch of a flagship product for a prestigious
OUR STRATEGIC international brand. Finally, in partnership with
FOOTHOLD IN ASIA a local distributor, Expanscience has established
a presence in Turkey to serve as a launching pad
for the markets in the Middle East.
With turnover that has doubled in
just two years, Asia has emerged as
Mustela’s second biggest marketing region after
Europe. This record can be attributed to Mustela
Bébé’s exceptionally strong performance in China
in 2015, with turnover up 180%. Expanscience has
invested heavily in the brand over the past three
years to increase its penetration rates at points of
sale and capture this extremely promising market
(with 16 million births annually). The market has
been boosted by increased buying power among
a substantial segment of the population, which is
increasingly turning to Premium products. On the
Asian continent as a whole, the Mustela Bébé and
DERMATOLOGY:
Maternity product lines have likewise posted strong OUR ADDITIONAL
growth, especially in Hong Kong and Taiwan. SKIN EXPERTISE
PIASCLÉDINE 300 In Southeast Asia, where In France, home to Effizinc, Doxylis Gé and
Expanscience relies on Procuta Gé, Expanscience offers a wide range of oral
a local distributor to market Piasclédine 300, the treatments for mild to severe acne in adolescents
year ended with a 300% increase in sales in Malaysia, and adults. In 2014 we expanded our portfolio
the Philippines and Vietnam. To coincide with of dermatological drugs with Finhair Gé, formulated
Piasclédine 300’s 2014 launch in Vietnam, two to treat androgenic alopecia in men ages 18 to 41.
scientific symposiums highlighting Expanscience’s Thanks to vigorous sales of Finhair Gé coupled with
expertise in osteoarthritis were held with increased market share for Effizinc and Doxylis Gé,
rheumatologists and other members of Vietnam’s the business line as a whole logged a 5% increase
medical community. In South Korea, where in turnover by drawing on its close relationships
Piasclédine 300 is sold under the name Imotun, the with dermatologists.
drug consolidated its position as market leader among
the products in its class over the past several years.
SPONSORSHIP

A COMMIT MENT
WITHOUT BORDE RS

CHILD DEVELOPMENT,
FAMILIES, PARENTHOOD, A PARTNER
SUPPORT FOR SENIORS... TO RESE ARCHERS
EXPANSCIENCE IS EXPANDING
ITS PHILANTHROPIC EFFORTS Each year the Fondation Mustela bestows awards and
IN WAYS THAT REFLECT ITS research grants for initiatives likely to have practical
applications that improve the treatment options available to
CORE IDENTITY. BOTH professionals in the field of child care and child health.
IN FRANCE AND WORLDWIDE,
In 2015 the foundation awarded two grants, one on how
ITS COMMITMENT TRANSLATES
children see health and another on parental bonds. The
INTO SUPPORT FOR RESEARCH foundation also announced two winners of its Maieutics
Prize in France for midwives. One prize was awarded to a
PROJECTS AND INITIATIVES LED
researcher examining the institution of the contemporary
BY HEALTHCARE PROFESSIONALS family, while the second went to a study of fungicides and
AND NON-GOVERNMENTAL their impact on child development.

ORGANIZATIONS. The Maieutics Prize is also awarded in Belgium and, as of 2015,

in Poland, where the maiden winner was a research project
to improve perinatal health. In addition, the Research Action

1982
Award, designed to support innovative initiatives for child
development within the family or institutional environment,
was given to a project studying ways to prevent conflicts
CREATION OF THE FONDATION MUSTELA in mother-child relationships.

"From physiological to psychological, cognitive and

120
emotional development: childhood in all its aspects
has been at the heart of the projects funded by the
Fondation Mustela for more than 30 years. As it has grown
and developed, the Fondation Mustela has continued to
AWARDS AND RESEARCH GRANTS support healthcare professionals and kept faith with its
GIVEN BY THE FONDATION determination to tackle new questions and introduce new
MUSTELA SINCE 1982 ways of working. Getting older while remaining young at
heart – surely that’s the best way to grow up."
IN THE FIELDS OF PSYCHOLOGY,
SOCIOLOGY, PSYCHIATRY Chantal Larcade
AND MAIEUTICS Chief Representative of the Fondation Mustela
 20
THE NUMBER OF COUNTRIES WHERE
PROJECTS HAVE RECEIVED SUPPORT
FROM THE FONDATION MUSTELA

ACTIVELY WORKING A REVAMPED

IN THE FIELD BOTH WEBSITE
IN FRANCE AND WORLDWIDE The Fondation Mustela’s website has been
completely redesigned to be more informative
for the general public. The site is available
in two versions, one for a general audience
The Fondation Mustela supports numerous initiatives targeted and the other for healthcare professionals,
to children and families and led by healthcare professionals or who can order information and prevention
select NGOs. In 2015, the foundation’s Social Pediatrics Prize packs at no charge or apply for
was awarded to Dr. Valentina Dell’Orto, a physician from the the foundation’s various grants and awards.
Hôpital Antoine-Béclère in Clamart, France, for her project With just a few clicks, visitors can learn
to prevent feeding difficulties in premature newborns. about the foundation’s various activities or
In Lebanon, the foundation renewed its support for ASMAE, view interactive media. Italian, Polish, Turkish,
a child protection organization associated with the NGO Dutch and Portuguese versions of the site
Soeur Emmanuelle. Always alert to international emergencies, are also available.
the Fondation Mustela also awarded an exceptional grant of Visit us at www.fondationmustela.com
€40,000 to Enfance Nepal in the wake of the earthquake that
struck the country on April 28, 2015.

With a presence in 20 countries, the Fondation Mustela has

lent support to several Expanscience subsidiaries, including A HISTORY OF SUPPORT
those in Italy (to help fund villages for abandoned children),
Portugal (for the well-being of young patients from families FOR DERMATOLOGICAL
experiencing difficulties) and Turkey (for early education for AND OSTEOARTHRITIS
women to boost their career prospects). At the same time,
it has worked with supply chains for plant raw materials
RESEARCH
to fund projects targeting local populations, in Burkina Faso As it has each year since 1998, Laboratoires
and elsewhere. Expanscience awarded two osteoarthritis
awards in 2015 for clinical and basic research,
The past year also saw the foundation step up its prevention totalling €3,820 each, along with an award
outreach initiatives for the general public, including the for dermatology research in the amount
reissue of an informative brochure to enhance the status of of €5,000. These awards are presented
the midwifery profession and the creation of an interactive in partnership with the Société Française
game for children, available at its website, to help them learn de Rhumatologie and the Société Française
about bodily hygiene. de Dermatologie respectively.
 Throughout
the world
FRANCE
10, avenue de l’Arche
92419 COURBEVOIE Cedex
•
AUSTRALIA
Suite 107-108
685 Burke Rd
Camberwell VIC 3124
•
BELGIQUE
SPHERE BUSINESS PARK
Z3 Doornveld 124 2C1
1731 ZELLIK
•
BRASIL
Rua Samuel Morse 74,
Conj. 162, Berrini
04576 060
SAO PAULO
•
CANADA
QC Montréal
2001 Boul. Robert Bourassa Suite 17069
MONTREAL – H3A 2A6
•
ESPAÑA
C/Marie Curie n°7
Edificio ß – 1a planta – oficina 1.6
28521 Rivas-Vaciamadrid, MADRID
•
ITALIA
Via Moncucco 20/22
20142 MILANO
•
MÉXICO
Amsterdam No 229, Piso 1– Col. Hipodromo
CP 06100 MEXICO, DF
•
POLSKA
UI. Żelazna 67/78
00-871 WARSZAWA
•
PORTUGAL
Avenida António Augusto de Aguiar Nº 21 – 4º Esq.
1050-012 LISBOA
•
SUISSE
Rue Jacques Grosselin, 8
CP 1035
1211 GENÈVE 26
•
TURKEY
Barbaros Mah. Kardelen Sok. No : 2
Palladium Tower Kat 18
34746 Atasehir, İSTANBUL
•
USA
60 East 56th Street, 6th Floor
New York, NEW YORK 10022
•
RUSSIA
Posledny Per., 11 b.1
107045, MOSCOW

www.expanscience.com